Tags

Type your tag names separated by a space and hit enter

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.
J Neurol 2006; 253(10):1337-41JN

Abstract

About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out). Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.

Authors+Show Affiliations

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. wissel@rehaklinik-beelitz.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16988792

Citation

Wissel, Jörg, et al. "Low Dose Treatment With the Synthetic Cannabinoid Nabilone Significantly Reduces Spasticity-related Pain : a Double-blind Placebo-controlled Cross-over Trial." Journal of Neurology, vol. 253, no. 10, 2006, pp. 1337-41.
Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253(10):1337-41.
Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. Journal of Neurology, 253(10), pp. 1337-41.
Wissel J, et al. Low Dose Treatment With the Synthetic Cannabinoid Nabilone Significantly Reduces Spasticity-related Pain : a Double-blind Placebo-controlled Cross-over Trial. J Neurol. 2006;253(10):1337-41. PubMed PMID: 16988792.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. AU - Wissel,Jörg, AU - Haydn,Tanja, AU - Müller,Jörg, AU - Brenneis,Christian, AU - Berger,Thomas, AU - Poewe,Werner, AU - Schelosky,Ludwig D, Y1 - 2006/09/20/ PY - 2005/11/25/received PY - 2006/03/02/accepted PY - 2006/9/22/pubmed PY - 2007/2/27/medline PY - 2006/9/22/entrez SP - 1337 EP - 41 JF - Journal of neurology JO - J. Neurol. VL - 253 IS - 10 N2 - About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out). Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable. SN - 0340-5354 UR - https://www.unboundmedicine.com/medline/citation/16988792/Low_dose_treatment_with_the_synthetic_cannabinoid_Nabilone_significantly_reduces_spasticity_related_pain_:_a_double_blind_placebo_controlled_cross_over_trial_ L2 - https://dx.doi.org/10.1007/s00415-006-0218-8 DB - PRIME DP - Unbound Medicine ER -